On Aug 21, 2013, we reaffirmed our long-term Neutral
) following mixed second-quarter results. This provider of
end-to-end automation solutions for the medication-use process
carries a Zacks Rank #3 (Hold).
On Aug 1, Omnicell posted second-quarter earnings of 19 cents,
flat year over year. The result missed the Zacks Consensus
Estimate by a couple of cents. Revenues climbed 24.3% to $93.7
million, ahead of the Zacks Consensus Estimate of $92 million.
While benefits from the MTS takeover led most of the revenue
upside for the company, contract wins and competitive conversions
supported organic growth. The consistent and solid top-line
growth reflects that Omnicell's three-pronged strategy of
domestic expansion, selective acquisitions and targeted
international expansion is yielding positive results. However,
the company maintained its expectations for 2013.
We are optimistic that footprint expansion in the international
market should foster growth over the long haul. The Middle East
and China present meaningful revenue opportunities for Omnicell.
On the tepid side, the company continues to battle escalating
costs. This might result in gross margin pressure in the upcoming
Moreover, constrained hospital expenditure due to a tough
macroeconomic backdrop across the globe might hamper Omnicell's
expansion plans. The ongoing hospital consolidation trend in the
U.S. might also result in volume pressure for the company.
Meanwhile, Omnicell continues to face competitive pressure from
larger players in the industry.
Stocks to Consider
While we remain on the sidelines for Omnicell, other stocks such
Gilead Sciences Inc.
) are worth considering. These stocks carry a Zacks Rank #1
AFFYMETRIX INC (AFFX): Free Stock Analysis
ALERE INC (ALR): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis
OMNICELL INC (OMCL): Free Stock Analysis
To read this article on Zacks.com click here.